San Diego-dependent Viking Therapeutics marked alone as a serious competitor within the weight loss drug market in February just after revealing promising information from a mid-stage trial of experimental drug VK2735, which suggested it rivaled—and outperformed—Novo and Lilly drugs when supplied to be a weekly injection As well as in March the